FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999647652> ?p ?o ?g. }

• W2999647652 abstract "Abstract Background Patients with Crohn’s disease (CD) may lose response to treatment, requiring dose adjustments. This analysis from the CELEST study evaluated efficacy and safety in patients with CD who required an escalated dose of upadacitinib (UPA), an oral selective JAK1 inhibitor. Methods CELEST (NCT02365649) was a placebo-controlled phase 2 study of adults with moderate-to-severe CD refractory to immunosuppressants/biologics. Patients were randomised to placebo or UPA 3, 6, 12, or 24 mg twice daily (BID) or 24mg once daily (QD) for 16 weeks (weeks), followed by a 36-week double-blind maintenance period to receive 3, 6 or 12mg BID or 24mg QD (Figure 1). Patients who met criteria for inadequate response (average daily liquid/soft stool frequency [SF] &gt;2.2 or average daily abdominal pain score &gt;1.8, and increase in hs-CRP &gt;1 mg/l from baseline [BL] or hs-CRP ≥5 mg/l at previous or current visit) at or after week 20 were eligible to receive open-label (OL) therapy with UPA 12mg BID. Patients with inadequate response at or after 4 weeks of OL 12 mg BID could further escalate to OL 24 mg BID. Data were analysed using descriptive statistics of clinical/endoscopic improvement, change from BL in hs-CRP and faecal calprotectin (FC), and AEs at week 52. Results Among 220 randomised patients, 180 were re-randomised into the maintenance period; 60 had inadequate response and received OL 12 mg BID. Of the 60 patients, 25 (42%) were in clinical response at week 16. After receiving OL 12 mg, 27 patients (45%) required escalation to OL 24 mg BID. A higher proportion of patients who received OL 24 mg received 2 or more prior TNF antagonists, and had higher BL FC, SF, and Simplified Endoscopic Score for CD (SES-CD) compared with patients who remained on OL 12 mg BID (Table 1). At week 52, 15% of patients who received OL 12 mg achieved clinical remission and 10% achieved endoscopic response. Of the patients who escalated to OL 24 mg, 39% achieved clinical remission and 41% were in endoscopic response at week 52 (Table 2). At week 52, change from BL in FC and hs-CRP was −2123 ± 2475 µg/g and −5.1 mg/l, respectively, for patients who received OL 24 mg vs. −423 ± 2953 and −6.4 mg/l for OL 12 mg. Serious infection was reported in 3 patients (2 receiving OL 12 mg and 1 receiving OL 24 mg). Two nonserious herpes zoster events were reported (1 on each dose), but neither event led to discontinuation of UPA. No malignancies, cardiovascular events, thromboembolic events, intestinal perforations, tuberculosis, or deaths were reported for patients who dose-escalated. Conclusion Patients with non-response or loss of response during CELEST gained clinical remission and endoscopic response with UPA 12 mg BID or further escalation to 24 mg BID. No new safety risks were observed for either dose of UPA, consistent with double-blind CELEST results." @default.
• W2999647652 created "2020-01-23" @default.
• W2999647652 creator A5032150391 @default.
• W2999647652 creator A5035492954 @default.
• W2999647652 creator A5045027763 @default.
• W2999647652 creator A5052062860 @default.
• W2999647652 creator A5062085496 @default.
• W2999647652 creator A5064013442 @default.
• W2999647652 creator A5065356435 @default.
• W2999647652 creator A5079859903 @default.
• W2999647652 creator A5088717074 @default.
• W2999647652 date "2020-01-01" @default.
• W2999647652 modified "2023-10-16" @default.
• W2999647652 title "DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study" @default.
• W2999647652 doi "https://doi.org/10.1093/ecco-jcc/jjz203.118" @default.
• W2999647652 hasPublicationYear "2020" @default.
• W2999647652 type Work @default.
• W2999647652 sameAs 2999647652 @default.
• W2999647652 citedByCount "0" @default.
• W2999647652 crossrefType "journal-article" @default.
• W2999647652 hasAuthorship W2999647652A5032150391 @default.
• W2999647652 hasAuthorship W2999647652A5035492954 @default.
• W2999647652 hasAuthorship W2999647652A5045027763 @default.
• W2999647652 hasAuthorship W2999647652A5052062860 @default.
• W2999647652 hasAuthorship W2999647652A5062085496 @default.
• W2999647652 hasAuthorship W2999647652A5064013442 @default.
• W2999647652 hasAuthorship W2999647652A5065356435 @default.
• W2999647652 hasAuthorship W2999647652A5079859903 @default.
• W2999647652 hasAuthorship W2999647652A5088717074 @default.
• W2999647652 hasBestOaLocation W29996476521 @default.
• W2999647652 hasConcept C121332964 @default.
• W2999647652 hasConcept C126322002 @default.
• W2999647652 hasConcept C142424586 @default.
• W2999647652 hasConcept C142724271 @default.
• W2999647652 hasConcept C197934379 @default.
• W2999647652 hasConcept C204787440 @default.
• W2999647652 hasConcept C27081682 @default.
• W2999647652 hasConcept C2778260677 @default.
• W2999647652 hasConcept C2778292693 @default.
• W2999647652 hasConcept C2779008522 @default.
• W2999647652 hasConcept C2779134260 @default.
• W2999647652 hasConcept C2779280984 @default.
• W2999647652 hasConcept C2780955771 @default.
• W2999647652 hasConcept C535046627 @default.
• W2999647652 hasConcept C71924100 @default.
• W2999647652 hasConcept C87355193 @default.
• W2999647652 hasConcept C90924648 @default.
• W2999647652 hasConceptScore W2999647652C121332964 @default.
• W2999647652 hasConceptScore W2999647652C126322002 @default.
• W2999647652 hasConceptScore W2999647652C142424586 @default.
• W2999647652 hasConceptScore W2999647652C142724271 @default.
• W2999647652 hasConceptScore W2999647652C197934379 @default.
• W2999647652 hasConceptScore W2999647652C204787440 @default.
• W2999647652 hasConceptScore W2999647652C27081682 @default.
• W2999647652 hasConceptScore W2999647652C2778260677 @default.
• W2999647652 hasConceptScore W2999647652C2778292693 @default.
• W2999647652 hasConceptScore W2999647652C2779008522 @default.
• W2999647652 hasConceptScore W2999647652C2779134260 @default.
• W2999647652 hasConceptScore W2999647652C2779280984 @default.
• W2999647652 hasConceptScore W2999647652C2780955771 @default.
• W2999647652 hasConceptScore W2999647652C535046627 @default.
• W2999647652 hasConceptScore W2999647652C71924100 @default.
• W2999647652 hasConceptScore W2999647652C87355193 @default.
• W2999647652 hasConceptScore W2999647652C90924648 @default.
• W2999647652 hasLocation W29996476521 @default.
• W2999647652 hasOpenAccess W2999647652 @default.
• W2999647652 hasPrimaryLocation W29996476521 @default.
• W2999647652 hasRelatedWork W11272766 @default.
• W2999647652 hasRelatedWork W13346190 @default.
• W2999647652 hasRelatedWork W16357959 @default.
• W2999647652 hasRelatedWork W17639579 @default.
• W2999647652 hasRelatedWork W19349779 @default.
• W2999647652 hasRelatedWork W5541502 @default.
• W2999647652 hasRelatedWork W7568419 @default.
• W2999647652 hasRelatedWork W7842801 @default.
• W2999647652 hasRelatedWork W8155901 @default.
• W2999647652 hasRelatedWork W9055210 @default.
• W2999647652 isParatext "false" @default.
• W2999647652 isRetracted "false" @default.
• W2999647652 magId "2999647652" @default.
• W2999647652 workType "article" @default.